Table 4. Duration and costs of drugs used among patients initiating treatment for MDR-TB disease (n = 62) at 3 treatment centers, Canada, July 2010–June 2016*.
| Drug | No. (%) patients receiving drug | Median (IQR) duration, mo | Cost, 2020 Canadian dollars |
|
|---|---|---|---|---|
| Median (IQR) cost per person | Mean cost per person | |||
| Amikacin | 58 (94) | 5.1 (2.6–8.2) | 4,024 (2,629–8,479) | 7,263 |
| Moxifloxacin | 58 (94) | 19.9 (8–22.4) | 809 (318–985) | 698 |
| Ethambutol | 56 (90) | 8.6 (1.1–15.9) | 280 (51–637) | 382 |
| Pyrazinamide | 53 (85) | 3.1 (0.8–8.8) | 217 (50–800) | 545 |
| Clofazimine | 50 (81) | 19.7 (6.8–22.6) | Given under compassionate use | |
| Isoniazid† | 47 (76) | 0.7 (0.4–1.7) | 14 (9–35) | 44 |
| Para-amino salicylic acid | 47 (76) | 13.6 (3.2–20.4) | 6,609 (1,917–11,411) | 7,036 |
| Rifampin† | 46 (74) | 0.7 (0.5–1.3) | 15 (9–35) | 37 |
| Cycloserine | 42 (68) | 13.4 (7–20.6) | 57,658 (28,942–91,935) | 61,590 |
| Ethionamide | 40 (65) | 11.3 (2.8–19.7) | 691 (191–1,304) | 785 |
| Linezolid | 34 (55) | 8.4 (3.5–16.2) | 10,057 (4,608–19,023) | 12,070 |
| Amoxicillin/clavulanate | 20 (32) | 14.3 (3.9–18.6) | 1,144 (286–1,652) | 1,524 |
| Imipenem/cilastatin | 14 (23) | 6.1 (1.8–7.3) | 8,459 (3,244–10,267) | 7,855 |
| Levofloxacin | 13 (21) | 11.4 (6.4–18.2) | 330 (69–1,328) | 1,022 |
| Clarithromycin | 10 (16) | 16.8 (3.4–21.8) | 2,711 (549–3,531) | 2,226 |
| Rifabutin | 5 (8) | 22.9 (22.7–23.7) | 13,207 (11,490–13,341) | 10,865 |
| Delamanid | 4 (6) | 3.7 (1.6–6.9) | 22,437 (5,616–38,475) | 21,654 |
| Azithromycin | 3 (5) | 9.5 (6.8–13.4) | 41 (29–3,850) | 2,572 |
| Bedaquiline | 3 (5) | 5.5 (3.9–5.5) | Given under compassionate use | |
| Meropenem | 3 (5) | 2.1 (1.3–10.2) | 21,123 (10,766–75,480) | 50,456 |
| Streptomycin | 2 (3) | 0.7 (0.4–1.1) | 980 (512–1,448) | 980 |
*IQR, interquartile range. †Stopped when resistance detected if treatment had been started before MDR TB confirmation.